Weight Watchers (WW) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
4 Jun, 2026Executive summary
Shareholders are urged to vote for all six director nominees and for the advisory vote on executive compensation at the 2026 Annual Meeting scheduled for June 12, 2026.
The Board highlights significant progress since the company's emergence from bankruptcy in June 2025, including a reconstituted Board and new executive compensation practices.
Leadership continuity is emphasized as critical during this transitional period, with a comprehensive CEO search underway.
Voting matters and shareholder proposals
Proposal 1 seeks election of six director nominees, including Eugene I. Davis and J. Carney Hawks.
Proposal 3 is an advisory vote to approve executive compensation (Say-on-Pay Proposal).
Proxy advisors ISS and Glass Lewis issued differing recommendations on director nominees and Say-on-Pay, with the Board disagreeing with ISS's negative recommendation.
Board of directors and corporate governance
Mr. Davis and Mr. Hawks were appointed to the Board and Compensation Committee post-bankruptcy, selected for their restructuring and governance expertise.
Both serve on the ad-hoc Transition Committee, overseeing the Interim Office of the CEO and leading the CEO search.
The Board believes their continued service provides stability and valuable leadership during a critical transition.
Latest events from Weight Watchers
- Q2 2026 saw revenue fall 14% but strong Clinical growth and reaffirmed guidance.WW
Q2 2026 - Settlement with former CEO includes major payments and mutual covenants amid leadership transition.WW
Proxy filing - Clinical growth and strong margins offset net loss; 2026 guidance and debt reduction reaffirmed.WW
Q1 2026 - Shareholders will vote on directors, auditor, and executive pay after a transformative restructuring.WW
Proxy filing - Clinical subscriber growth and higher ARPU drive 2026 outlook despite behavioral headwinds.WW
Q4 2025 - GLP-1 integration, financial restructuring, and targeted programs drive innovation and growth.WW
CJS Securities 26th Annual "New Ideas for the New Year” Investor Conference - Q3 revenue and subscribers fell, but clinical growth and cost actions supported margin gains.WW
Q3 2024 - Q2 2024 revenue fell 10.9% as clinical subscribers surged 120% and cost savings were targeted.WW
Q2 2024 - Clinical growth and cost cuts offset declines, but bankruptcy and high debt loom.WW
Q1 2025